80 Years and Older Vision & Hearing Important Persons Project (80VIP)

项目总结/摘要 以前的患病率研究仅包括对视力、听力、平衡丧失或 双重感觉丧失（DSL）在80岁以上的老年人，这造成了很大的差距，在这方面的知识 重要的年龄组。这一年龄组将在未来30年内增加600%，增长速度超过任何 其他年龄层或少数群体。许多老年患者入院接受机构化护理， 未处理的VL/HL/DSL的比例。不幸的是，关于治疗VL/HL/DSL的有效性的数据很少 降低发病率，提高生活质量，并减少照顾者的负担和成本，在这个敏感的年龄 组这表明有必要了解未诊断的VL/HL/DSL的患病率和影响， 居住在社区的老年人。与听力和视力有关的障碍将分别排在前10位 在未来20年中，中等收入和高收入国家的疾病负担。对老年人的这种评价 符合美国国立卫生研究院新的“终身包容”政策，该政策于 2019年1月。 R34规划补助金是为了支持未来80年详细基础设施的发展， 老年人视力和听力重要人士项目（80 VIP）根据UG 1合作协议资助 机制这一特殊人群（年龄>80岁）很少被纳入基于人口的流行率调查 或临床试验，可能需要更多的努力，或新的方法来招募和登记参与者时， 以前的研究。我们还将制定一份全面的程序手册，其中包括以下标准： 收集眼睛和生物特征数据，包括新的仪器，并允许与以前的比较， 开创性的流行率调查。我们还将评估该方案的负担、可行性和适用性 从关键利益攸关方的角度来看，这增加了成功过渡到 更大的UG 1研究;我们将制定一个统计分析计划，解决所有拟议的未来 假设研究小组有专业知识来进行这项提案，并提出这项规划补助金提案 成功申请UG 1未来，该提案的经验和数据将有助于规划 未来的卫生资源需求，以及加强健康生活、预防发病 例如机构化护理，并降低视力和听力损失的高昂经济成本。

Project Summary/Abstract Previous prevalence studies include only small and infrequent estimates of vision, hearing, balance loss or dual sensory loss (DSL) in older adults over aged 80 years, which creates a large gap in knowledge in this important age group. This age group will increase by 600% in the next 30 years, an increase faster than any other age strata, or minority group. Many older patients admitted into institutionalized care have high proportions of untreated VL/HL/DSL. Unfortunately, little data exists on the effectiveness of treating VL/HL/DSL to decrease morbidity, increase quality of life, and decrease caregiver burden and cost in this susceptible age group. This demonstrates a need to understand the prevalence and impact of undiagnosed VL/HL/DSL in community dwelling older adults. Age-related hearing and vision impairment will each rank within the top 10 burdens of disease in middle- and high-income countries in the next 20 years. This evaluation of older persons fits with the National Institutes of Health's new "Inclusion Across the Lifespan" policy that was implemented in January 2019. The R34 planning grant is to support the development of a detailed infrastructure for a future ‘80 Years and Older Vision & Hearing Important Persons Project (80VIP)’ under the UG1 Cooperative Agreement funding mechanism. This special population (age >80 years) is rarely included in population-based prevalence surveys or clinical trials, and may require more effort, or new methods to recruit and enroll participants when compared to previous studies. We will also develop a comprehensive manual of procedures, which includes standards for collecting ocular and biometric data, includes new instrumentation, and allows comparisons with previous groundbreaking prevalence surveys. We will also evaluate the burden, feasibility, and suitability of the protocol from the perspective of key stakeholders, which increases the likelihood of a successfully transition into a larger UG1 study; and we will develop a statistical analysis plan that addresses all of the proposed future hypotheses. The study team has the expertise to conduct this proposal, and move this planning grant proposal toward a successful UG1 application. In the future, the experiences and data from this proposal will help plan health resources requirements in the future, and interventions to augment healthy living, prevent morbidity such as institutionalized care, and reduce the high economic costs of vision and hearing loss.